SucralfateMarket, by Formulation (Tablet and Liquid), by Indication (Gastric Ulcers,Duodenal Ulcers, Gastro Esophageal Reflux Disease (GERD), and OtherIndications), and by Region (North America, Europe, Asia Pacific, LatinAmerica, Middle East, and Africa) - Size, Share, Outlook, and OpportunityAnalysis 2018 – 2026
Sucralfate is the generic form ofthe brand-name drug, Carafate. It is a prescription medicine used to treatulcers of the upper gastrointestinal tract, peptic ulcer disease, and toprevent reoccurrence of ulcers. Sucralfate is a hydroxy aluminum salt ofsucrose octasulfate that functions as a local mucosal adherent. It forms acoating over ulcers by sticking to the affected area, which protects the areafrom acid and enzymes and helps ulcers to heal more quickly.
Sucralfate can also be used intreating ulcers and upper gastrointestinal disorders of dog, horse, and cat,which may arise due to drugs (particularly non-steroidal anti-inflammatorydrugs (NSAIDs) and corticosteroids), toxic chemical ingestion, liver disease,renal failure, carcinoma, stress (trauma, shock, sepsis, and burns), andinflammatory bowel disease.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2325
Sucralfate Market Drivers
Increasing research anddevelopment activities for discovering new medicine using sucralfate isexpected to propel growth of the sucralfate market. For instance, according tothe American Broncho Esophagological Association report in April 2018, use of sucralfatealong with honey aids in treatment of esophageal injury in infants andchildren. Esophageal injury in infants and children is associated withconsumption of Button Batteries (BB), small disc-shaped batteries commonlyfound in toys. Use of sucralfate with honey can help in mitigation of thebutton batteries and allows symptomatic relief from esophageal injury.
Sucralfate Market Restraint
Drug shortages are projected tohinder growth of the sucralfate market. For instance, according to DrugShortages Canada, report of September 2018, APO-SUCRALFATE - TAB 1G (APOTEXINC) that contained sucralfate was not available due to disruption in themanufacturing of the drug. The drug is used to treat peptic ulcer and gastro esophagealreflux disease (GERD).
Sucralfate Market – RegionalAnalysis
On the basis of region, theglobal sucralfate market is segmented into North America, Latin America,Europe, Asia Pacific, Middle East, and Africa.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/sucralfate-market-2325
North America is expected to holddominant position in the sucralfate market, owing to increasing number ofclinical studies. For instance, University of Texas is conducting a clinicalphase II study on sucralfate to improve oral intake in children with infectiousoral ulcers. The study is expected to be completed by June 2019.
By 2026, Asia Pacific is expectedto witness significant growth in the global sucralfate market due to increasingprevalence of H. pylori associated peptic ulcer disease, gastric cancer, andgastric mucosa-associated lymphoid tissue (MALT) lymphoma.
Key players operating in theglobal sucralfate market include, SRL Pharma, Nitika Chemicals., TevaPharmaceutical Industries Ltd., Lisapharma S.p.A, Aptalis Pharma US, Inc.,Uniprix Group, Rx Outreach, Abcam Plc, and Quimica Alkano.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2325
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
